Naltrexone Implants — CPB 0878 | AETNA Coverage Update

TL;DR: Aetna modified CPB 0878 on January 5, 2026, confirming that naltrexone implants remain non-covered across all indications — including opioid and alcohol addiction. If your billing team submits claims for naltrexone implant procedures under any ICD-10 codes in the F10–F15 range or others listed in this policy, expect denial.

This update reinforces Aetna's position that naltrexone implants are experimental, investigational, or unproven. No CPT or HCPCS procedure codes are separately designated as covered under CPB 0878 — the entire modality is excluded. One critical carve-out: this policy does not apply to Vivitrol injections billed under J2315 or other commercially available naltrexone formulations. That distinction matters more than you might think.

Note: "Aetna, a CVS Health company" is a commonly used descriptor. This language does not appear in CPB 0878. Refer to Aetna's official policy documentation for the payer's current formal name.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Naltrexone Implants — CPB 0878
Policy Code	CPB 0878
Change Type	Modified
Effective Date	January 5, 2026
Impact Level	High — complete non-coverage across all indications
Specialties Affected	Addiction medicine, psychiatry, neurology, endocrinology, pain management
Key Action	Flag all naltrexone implant claims in your charge capture and route patients to covered alternatives (e.g., Vivitrol/J2315) before billing

---

Aetna Naltrexone Implants Coverage Criteria and Medical Necessity Requirements 2026

Here's the short version: there are no covered indications under this policy. Aetna's position is that naltrexone implants fail to meet medical necessity standards across every condition listed in CPB 0878. That list includes alcohol dependence, narcotic addiction, amphetamine use, autism spectrum disorders, buprenorphine dependence, fentanyl-induced respiratory depression, impulse control disorders in Parkinson disease, prolactinoma, and trichotillomania.

The policy explicitly notes this is "not an all-inclusive list." That language is important. Aetna can deny naltrexone implant claims for conditions not on this list under the same experimental designation. Don't assume a diagnosis outside the list creates a coverage opportunity.

The rationale is insufficient evidence in peer-reviewed published medical literature. Aetna cites unestablished safety and effectiveness — the standard language they use when a treatment hasn't cleared their evidence threshold.

CPB 0878 does not address prior authorization pathways. What the policy does state is that naltrexone implants are classified as experimental, investigational, or unproven — which means the modality itself is excluded, not just specific uses of it. For questions about whether a prior authorization pathway exists for naltrexone implants under a specific Aetna plan, confirm directly with Aetna. Do not assume a PA submission will change the outcome without verifying that with the payer first.

Reimbursement for naltrexone implants under Aetna plans is effectively zero. If you're billing these procedures and expecting payment, the claim denial is coming. The question is whether you're catching it before or after it hits your AR.

---

Aetna Naltrexone Implants Exclusions and Non-Covered Indications

The full exclusion list under CPB 0878 covers nine named conditions plus an open-ended "not all-inclusive" qualifier. Every one of them is classified as experimental, investigational, or unproven. These claims will not pay.

Alcohol addiction (F10.20–F10.29): The entire F10 alcohol dependence code family is listed. If your practice treats alcohol use disorder and has explored naltrexone implants as a treatment option, this is your denial risk.

Narcotic and opioid addiction (F11.10–F11.99): Aetna lists opioid abuse (F11.10–F11.19), drug dependence (F11.20–F11.29), and opioid use unspecified (F11.90–F11.99). That's 30 ICD-10 codes covering the full spectrum of opioid use disorder billing.

Amphetamine use (F15.10–F15.18): Stimulant abuse codes in the F15.1x range are included. This is relevant for addiction medicine practices working with stimulant use disorder patients.

Other drug dependence (F12–F14): The policy captures drug dependence codes in the F12.20–F12.29, F13.20–F13.29, and F14.20–F14.29 ranges. All are non-covered when paired with a naltrexone implant claim.

Prolactinoma (D35.2): This one surprises some practices. Prolactin-secreting pituitary tumors appear in this policy because naltrexone has been studied — without sufficient evidence — as a treatment for prolactinoma. Endocrinology practices should note this.

Autism spectrum disorders, trichotillomania, and impulse control disorders in Parkinson disease: These behavioral health indications extend the policy beyond addiction medicine into psychiatry and neurology. If your team treats these conditions and has considered naltrexone implants, the Aetna naltrexone implants coverage policy closes that door completely.

Buprenorphine dependence and fentanyl-induced respiratory depression: These indications are in CPB 0878 specifically because naltrexone has been researched — without clinical consensus — as a treatment for these conditions. The denial rationale is the same: insufficient peer-reviewed evidence.

---

Coverage Indications at a Glance

---

Aetna Naltrexone Implants Billing Guidelines and Action Items 2026

This policy is not ambiguous — naltrexone implants are excluded. Your action items here are about protecting your AR and making sure your team isn't wasting time chasing claims that Aetna has already decided won't pay.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Naltrexone Implants Under CPB 0878

Covered Procedure Codes

CPB 0878 lists no covered CPT or HCPCS procedure codes for naltrexone implants. The policy does not designate any implant procedure as covered under any circumstance.

Excluded / Out-of-Scope Procedure Codes

Code	Type	Description	Notes Copy
J2315	HCPCS	Injection, naltrexone, depot form, 1 mg (Vivitrol)	Explicitly excluded from CPB 0878 scope — billed separately, subject to different coverage rules

Key ICD-10-CM Diagnosis Codes Listed in CPB 0878

These codes appear in the policy. Any naltrexone implant claim submitted with these diagnoses will be denied under the experimental/investigational designation.

Note: Code descriptions below reflect the source policy's grouping labels only — not full ICD-10-CM clinical descriptions. The source policy uses summary labels such as "Alcohol dependence," "Opioid abuse," "Drug dependence," and "Stimulant abuse [amphetamine]" for these code ranges. For complete subcategory-level descriptions, refer to the official CPB 0878 document and your ICD-10-CM reference.

The policy data references 134 total ICD-10-CM codes. The 54 additional codes beyond those listed above follow the same pattern across additional F-code subcategories. Use the full CPB 0878 policy document at app.payerpolicy.org/p/aetna/0878. for the complete code set before finalizing your charge capture audits.

---